title: Comparison of plasma aldosterone concentration among clinical status groups of dogs with chronic heart failure.
abstract: The plasma aldosterone concentration (PAC) among clinical status groups of 23 dogs with chronic heart failure was compared at various times after diagnosis of the problem. Eighteen dogs admitted in New York Heart Association (NYHA) class IV clinical status had significant elevations in PAC (P<0.0001), when compared with clinically normal dogs. Five dogs admitted in NYHA class III status and 4 dogs that responded with a change to NYHA class III status had significant elevations in PAC (P<0.01), when compared with clinically normal dogs. In patients with NYHA class IV status, the PAC was significantly greater (P<0.01) than in patients in NYHA class III status. For patients with the poorest prognosis, ie, severe signs of NYHA class IV status, the PAC was not markedly different, when compared with that for patients with a favorable prognosis, ie, recent onset of signs of NYHA class IV status. Patients treated with captopril had significantly lower PAC after therapy (P<0.01), whereas patients treated with hydralazine had significantly higher PAC (P<0.05) after therapy. It was concluded that heart failure in the dog increases PAC, most likely because of renin-angiotensin-aldosterone-system activation, and that the increase is related directly to the clinical status of the patient. Further, it was concluded that treatment of dogs in heart failure with captopril causes a decrease in circulating PAC, whereas treatment with hydralazine causes an increase in circulating PAC.
authors: Department of Small Animal Clinical Sciences, College of Veterinary Medicine, Michigan State University, East Lansing 48824, USA.
authors: G G
authors: GG
authors: Knowlen
authors: M D
authors: MD
authors: Kittleson
authors: R F
authors: RF
authors: Nachreiner
authors: G E
authors: GE
authors: Eyster
mesh_terms: D000450:Aldosterone / Q000097:blood*; D000806:Angiotensin-Converting Enzyme Inhibitors / Q000627:therapeutic use*; D000818:Animals; D000959:Antihypertensive Agents / Q000627:therapeutic use*; D002216:Captopril / Q000627:therapeutic use; D002908:Chronic Disease; D004283:Dog Diseases / Q000097:blood* / Q000188:drug therapy; D004285:Dogs; D005260:Female; D006331:Heart Diseases / Q000097:blood / Q000188:drug therapy / Q000662:veterinary*; D006830:Hydralazine / Q000627:therapeutic use; D008297:Male; D011379:Prognosis
chemical_list: D000806:Angiotensin-Converting Enzyme Inhibitors; D000959:Antihypertensive Agents; D006830:Hydralazine; D000450:Aldosterone; D002216:Captopril